Exploring the Role of HSD17B2 in Colorectal Cancer Through Bioinformatic Analysis: Preliminary Insights for Prognostic Evaluation

Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the second leading cause of cancer-related mortality worldwide. Although screening has reduced CRC in older adults, cases in younger individuals are rising, highlighting the need for early biomarkers. Emerging research highlights the role of estrogen metabolism in CRC progression, with enzymes such as hydroxysteroid (17-beta) dehydrogenase (HSD17B) being increasingly implicated. In this study, we performed a bioinformatics analysis using publicly available datasets, including The Cancer Genome Atlas Colon Adenocarcinoma (TCGA-COAD) cohort and two independent Gene Expression Omnibus (GEO) cohorts (GSE40967 and GSE41258), to investigate the role of HSD17B enzymes in CRC. Our results suggest that HSD17B2 is frequently downregulated in precancerous lesions and early-stage CRC, which may contribute to elevated estradiol levels and a tumor-promoting microenvironment. In advanced stages, higher HSD17B2 expression levels are associated with poorer survival outcomes in retrospective cohorts. Other HSD17B enzymes also exhibit significant expression changes, further complicating the hormonal landscape of CRC. In addition, estrone, traditionally considered a weaker estrogen, emerges as a potential driver of CRC progression. Our in-silico analyses indicate that HSD17B2 and HSD17B11 warrant further investigation as candidate biomarkers for distinguishing CRC from benign and precancerous conditions, with the combination showing strong discriminatory power in Receiver Operating Characteristic (ROC) analyses. Overall, these findings highlight the potential role of estrogen metabolism in CRC and suggest that HSD17B enzymes may hold value as candidate prognostic and diagnostic indicators, though their clinical utility remains hypothetical at this stage. Experimental and clinical validation is strictly required to confirm these in silico observations and to clarify their mechanisms in CRC.

Authors

Institutions

Publication Details

Journal
International Journal of Molecular Sciences
Published
2026-08-25
DOI
https://doi.org/10.3390/ijms27177614
Primary Topic
Estrogen and related hormone effects
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Exploring the Role of HSD17B2 in Colorectal Cancer Through Bioinformatic Analysis: Preliminary Insights for Prognostic Evaluation

Manuel Picon‐Ruiz, Ana Belén Diaz-Ruano, Alfonso Rubio‐Navarro, Juan Antonio Marchal et al.
International Journal of Molecular Sciences
Estrogen and related hormone effects
article

Exploring the Role of HSD17B2 in Colorectal Cancer Through Bioinformatic Analysis: Preliminary Insights for Prognostic Evaluation

Manuel Picon‐Ruiz, Ana Belén Diaz-Ruano, Alfonso Rubio‐Navarro, Juan Antonio Marchal, Eliana Gomez-Jimenez, Maria Paz Zafra, Giselle Xavier-Reis, Nieves Casillas-Ruiz, Noelia Garcia-Mascaraque, Alba Hidalgo-Ramirez
article en

Abstract

Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the second leading cause of cancer-related mortality worldwide. Although screening has reduced CRC in older adults, cases in younger individuals are rising, highlighting the need for early biomarkers. Emerging research highlights the role of estrogen metabolism in CRC progression, with enzymes such as hydroxysteroid (17-beta) dehydrogenase (HSD17B) being increasingly implicated. In this study, we performed a bioinformatics analysis using publicly available datasets, including The Cancer Genome Atlas Colon Adenocarcinoma (TCGA-COAD) cohort and two independent Gene Expression Omnibus (GEO) cohorts (GSE40967 and GSE41258), to investigate the role of HSD17B enzymes in CRC. Our results suggest that HSD17B2 is frequently downregulated in precancerous lesions and early-stage CRC, which may contribute to elevated estradiol levels and a tumor-promoting microenvironment. In advanced stages, higher HSD17B2 expression levels are associated with poorer survival outcomes in retrospective cohorts. Other HSD17B enzymes also exhibit significant expression changes, further complicating the hormonal landscape of CRC. In addition, estrone, traditionally considered a weaker estrogen, emerges as a potential driver of CRC progression. Our in-silico analyses indicate that HSD17B2 and HSD17B11 warrant further investigation as candidate biomarkers for distinguishing CRC from benign and precancerous conditions, with the combination showing strong discriminatory power in Receiver Operating Characteristic (ROC) analyses. Overall, these findings highlight the potential role of estrogen metabolism in CRC and suggest that HSD17B enzymes may hold value as candidate prognostic and diagnostic indicators, though their clinical utility remains hypothetical at this stage. Experimental and clinical validation is strictly required to confirm these in silico observations and to clarify their mechanisms in CRC.

International Journal of Molecular SciencesVol. 27(17)
Universidad de Granada (ES), Instituto de Investigación Biosanitaria de Granada (ES)
European Commission, Instituto de Salud Carlos III
Reduced inequalities
Openalex Percentile: Top 10%
Estrogen and related hormone effects
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.